Amgen Financial Results: Q1 2026 Performance Br...

By HEOR Staff Writer

May 4, 2026

Amgen financial results for the first quarter of 2026 reveal strong performance. Revenues increased 6% to $8.6 billion. Product sales grew 4%. Volume drove most of this growth. The company generated $1.5 billion in free cash flow (Amgen, 2026).
Gaps in AI Governance Healthcare Frameworks: Ensuring Effective Implementatio...
Merck Q1 2026 Performance: Growth and Innovations in Oncology and Cardiometab...
Advancing High-Risk Oncology Interventions: Promising Developments from ASCO ...
TikTok Opioid Overdose Forecasting: Leveraging Social Media Data for Enhanced...
Regulatory Divergence in PSMA Targeted Therapy: Implications for European Mar...
PIONEER TEENS Trial Reveals Oral Semaglutide Diabetes Breakthrough for Pediat...
Terminal Complement Inhibition: Promising Results in IgAN from the I CAN Trial
Advancing Multicenter AKI Prediction: Benefits of Collaborative Models Over L...
Advancements in HIV Two-Drug Regimen: FDA Approves IDVYNSO for Virologically ...
Progress and Challenges in the FDA Accelerated Approval Pathway: A Policy Roa...
Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
Effective Hypertension Control Interventions in Underserved Populations